Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329816 | 0.92 | PTGDR2 (0.48) | PTGDR2MAPTPOLBSMN1; SMN2TSHR | |
| SCHEMBL2367582 | 0.91 | KCNH2 (0.48) | KCNH2PTGDR2MAPTMEN1MAPK1 | |
| SCHEMBL2367082 | 0.89 | KCNH2 (0.47) | KCNH2PTGDR2MAPTMEN1MAPK1 | |
| SCHEMBL2367556 | 0.87 | MAPT (0.54) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL31414362 | 0.87 | MAPT (0.54) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2367720 | 0.85 | PTGDR2 (0.54) | PTGDR2MAPTALDH1A1TP53 | |
| SCHEMBL15484853 | 0.85 | MAPT (0.54) | PTGDR2MAPTMEN1KMT2APOLB | |
| SCHEMBL1923270 | 0.83 | PTGDR2 (0.47) | PTGDR2MAPTMEN1MAPK1KMT2A | |
| SCHEMBL15334251 | 0.83 | MAPT (0.46) | PTGDR2MAPTMEN1MAPK1KMT2A | |
| SCHEMBL2367664 | 0.83 | MAPT (0.48) | PTGDR2MAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | claimed |
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | KCNH2 1176/4885PTGDR2 1106/4885MAPT 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.